tradingkey.logo

Codexis Inc

CDXS
查看詳細走勢圖
1.330USD
+0.060+4.72%
收盤 02/06, 16:00美東報價延遲15分鐘
120.07M總市值
虧損本益比TTM

Codexis Inc

1.330
+0.060+4.72%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+4.72%

5天

+7.26%

1月

-21.76%

6月

-52.16%

今年開始到現在

-18.40%

1年

-69.21%

查看詳細走勢圖

TradingKey Codexis Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Codexis Inc當前公司基本面數據相對穩定,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名99/392位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為6.58。中期看,股價處於下降通道。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Codexis Inc評分

相關信息

行業排名
99 / 392
全市場排名
228 / 4521
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

Codexis Inc亮點

亮點風險
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
業績增長期
公司處於發展階段,最新年度總收入59.34M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入59.34M美元
估值高估
公司最新PE估值-1.81,處於3年歷史高位
機構減倉
最新機構持股63.79M股,環比減少4.77%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉8.40K股
活躍度增加
近期活躍度增加,過去20天平均換手率0.67

分析師目標

基於 7 分析師
買入
評級
6.583
目標均價
+398.74%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Codexis Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Codexis Inc簡介

Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
公司代碼CDXS
公司Codexis Inc
CEOMoore (Alison)
網址https://www.codexis.com/
KeyAI